First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors.

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Biology

Cancer Oncology

Medicine

Molecular Biology

Polymerase

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.tps3174